Clinical trials: Neurologic Symptoms
Myotonic Dystrophy Type 1, DM1
Global Open-Label Extension Study of Del-desiran for the Treatment of DM1
A Global Phase 3 Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Intravenous Delpacibart Etedesiran (abbreviated del-desiran, formerly AOC 1001) for the Treatment of Myotonic Dystrophy…
- Conditions
- Myotonic Dystrophy Type 1, DM1, Myotonic Dystrophy, Myotonia
- Trial name
- HARBOR-OLE (NCT07008469)
- Testing
- Del-desiran (AOC 1001)
- Where
- 35 sites in United States, Canada and 8 more
- Volunteers
- 199 people
- Sponsor
- Avidity Biosciences, Inc.
Atherosclerotic Coronary Vascular Disease
Evaluation of Exercise Treadmill Test (ETT) Indices in Participants With Cardiovascular Disease
The study was designed to evaluate the use of ETT electrocardiogram (ECG) indices as biomarkers in the assessment of atherosclerotic coronary vascular disease (ASCVD).
- Trial name
- NCT01562041
- Testing
- Ranolazine 500 mg
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Novartis Pharmaceuticals
Cerebral Infarction
Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke
This study is randomized, Sodium Ozagrel (Thromboxane A2 Synthase Inhibitor) controlled study on acute ischemic stroke. The primary endpoints were the rate of patients with modified Rankin Scale score of 0-1 at 3 months.
- Trial name
- NCT00200356
- Testing
- Edaravone, Sodium Ozagrel
- Volunteers
- 401 people
- Sponsor
- Shionogi
Pain
Study To Evaluate Efficacy And Safety Of An Additional Dose Of Celecoxib (YM177) In Patients With Post-Tooth Extraction Pain
To evaluate efficacy and safety of additional dose of celecoxib, as compared to placebo, in patients with post lateral mandibular impacted third molar tooth extraction pain.
- Trial name
- NCT01062113
- Testing
- Celecoxib
- Where
- 22 sites in Japan
- Volunteers
- 255 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Seizures
Effectiveness and Safety Study for RWJ-333369 as Adjunctive Therapy in Korean and Japanese Patients With Partial Onset Seizures
The purpose of the study is to evaluate the effectiveness and safety of adjunctive RWJ-333369 at a dose of 200 or 400 mg/day in comparison with placebo in Korean and Japanese partial epilepsy patients who have poor seizure…
- Trial name
- NCT00697762
- Testing
- RWJ-333369
- Volunteers
- 56 people
- Sponsor
- SK Life Science, Inc.
Myocardial Infarction, Cardiovascular Death
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
This study is being carried out to see if a new drug called ticagrelor given twice daily in addition to the ASA therapy decreases the frequency of cardiovascular events (e.g., death from heart disease, heart attack, or stroke).
- Conditions
- Myocardial Infarction, Cardiovascular Death, Atherothrombosis, Stroke
- Trial name
- PEGASUS (NCT01225562)
- Testing
- Ticagrelor 90 mg, Ticagrelor 60 mg
- Where
- 826 sites in United States, Argentina and 29 more
- Volunteers
- 21,379 people
- Sponsor
- AstraZeneca
Musculoskeletal Injury, Pain, Chronic
Real-World Experience of Patients Treated for Musculoskeletal Injuries With SAM in Routine Care
The purpose of this study is to evaluate continuous ultrasound treatment with diclofenac coupling patch during routine care of musculoskeletal injuries which failed conservative treatment to better understand clinical utilization…
- Conditions
- Musculoskeletal Injury, Pain, Chronic, Pain, Acute, Sport Injury
- Trial name
- NCT05254470
- Testing
- Continuous Ultrasound
- Where
- United States
- Volunteers
- 135 people
- Sponsor
- ZetrOZ, Inc.
Refractory Partial Seizures
To Evaluate The Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
The purpose of this study is to evaluate the efficacy, safety and tolerability of perampanel when given as an adjunctive therapy in subjects with refractory partial seizures.
- Trial name
- NCT00699582
- Testing
- E2007 (perampanel)
- Where
- 92 sites in United States, Austria and 12 more
- Volunteers
- 389 people
- Sponsor
- Eisai Inc.
Hearing Loss, Sensorineural
Evaluation of the Efficacy and Safety of the Sullivan Cochlear Implant.
The study will be conducted as a prospective, single center, repeat measure, single-arm, open label clinical study
- Trial name
- NCT07018882
- Testing
- Sullivan
- Volunteers
- 25 people
- Sponsor
- Todoc
Alzheimer's Disease
A Safety and Efficacy Study of Oral Dimebon in Patients With Mild-To-Moderate Alzheimer's Disease
The Connection Study is a six-month confirmatory Phase 3 study to determine the safety and efficacy of Dimebon in the treatment of mild-to-moderate Alzheimer's disease (AD).
- Trial name
- CONNECTION (NCT00675623)
- Testing
- Dimebon
- Where
- 28 sites in United States
- Volunteers
- 598 people
- Sponsor
- Medivation, Inc.
Health-related Quality of Life, Pain
Outcomes During Digitally Delivered Osteoarthritis Treatment
Objectives: To examine changes in health-related quality of life (HRQL), pain and function among patients with knee or hip osteoarthritis (OA) participating in digitally delivered exercise and education treatment for up to 12 or…
- Conditions
- Health-related Quality of Life, Pain, Function, Osteoarthritis, Knee
- Trial name
- NCT05026580
- Testing
- Joint Academy exercise and education smart phone application
- Where
- Sweden
- Sponsor
- Joint Academy
Low Back Pain
A Trial Comparing Three Orthobiologic Therapies on Atrophied Multifidus Muscles in Patients With Low Back Pain
To evaluate and compare the effectiveness of 3 different injection treatments on multifidus atrophy and lower back pain.
- Trial name
- NCT03618979
- Testing
- PPP treatment, PRP treatment, PRP and PL Combo treatment
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Regenexx, LLC
Low Back Pain
A Study to Investigate the Effect of a New Postural Bio-feedback Device on Low Back Pain
A postural bio-feedback device worn by subjects for 4-10 hours a day for 6 days spread across 6 weeks for the sub acute low back pain group and for 8 days spread across 10 weeks for the chronic group.
- Trial name
- NCT01572779
- Testing
- BSM device with bio-feedback, BSM device with no bio-feedback
- Where
- 9 sites in Australia
- Volunteers
- 112 people
- Sponsor
- Pro-Active Medical Pty Ltd
Intracranial Aneurysm, Brain Arterial Disease
Safety, Performance and Usability of BALT Medical Devices: The EVIDENCE Post Marketing Clinical Follow-up Platform
BALT has designed an electronic platform to continue collecting clinical data as part of the post-marketing clinical follow-up of its devices.
- Conditions
- Intracranial Aneurysm, Brain Arterial Disease, Acute Ischemic Stroke, Peripheral Vascular Diseases
- Trial name
- EVIDENCE (NCT04927156)
- Testing
- BALT medical devices
- Where
- 12 sites in France, Germany and 1 more
- Volunteers
- 10,000 people
- Sponsor
- Balt Extrusion
Amblyopia, Anisometropic, Amblyopia Strabismic
Validation of New Virtual Reality Treatment for Children With Lazy Eye Using the Vedea Amblyopia Therapy (VAT)
The purpose of this clinical study is to validate the effectiveness of the Vedea Amblyopia Therapy (VAT) as a treatment for children with lazy eye.
- Conditions
- Amblyopia, Anisometropic, Amblyopia Strabismic, Amblyopia
- Trial name
- VAT (NCT05620173)
- Testing
- Vedea Amblyopia Therapy (VAT), Occlusion therapy
- Where
- 2 sites in Netherlands
- Volunteers
- 74 people
- Sponsor
- Vedea Healthware BV
Sleep Disorders
Validation of Ambulatory Sleep Test (WP200/U) Compared In-lab Sleep Testing in Cardiac Subjects
Subjects with cardiac disorders will be tested in the sleep laboratory with a conventional full-night PSG recording along with WP 200/WP200U ambulatory sleep diagnostic device in a synchronized manner.
- Trial name
- NCT02369705
- Where
- 10 sites in United States, Canada and 2 more
- Volunteers
- 200 people
- Sponsor
- Itamar-Medical, Israel
Pathologic Processes, Diabetes Mellitus
Clinical Trial Assessing Human Placental Membrane Products and Standard of Care Versus Standard of Care in Nonhealing DFUs and VLUs
The purpose of the study is to evaluate the efficacy of multiple human placental membrane products and Standard of Care (SOC) versus SOC alone in the management of nonhealing diabetic foot ulcers (DFUs) and venous leg ulcers…
- Conditions
- Pathologic Processes, Diabetes Mellitus, Glucose Metabolism Disorders, Metabolic Diseases
- Trial name
- C5CAMP (NCT06674980)
- Testing
- Standard of Care - DFU, AM/Single - DFU, AM/Double - DFU
- Where
- United States
- Volunteers
- 177 people
- Sponsor
- C5 Biomedical
Multiple Sclerosis, Radiologically Isolated Syndrome
Clinical Impact Through AI-assisted MS Care - A Prospective Multi-center Study
The goal of the PROCLAIM study is to assess the effectiveness of quantitative brain MRI, as measured by icobrain mr, on the detection of disease activity in multiple sclerosis, including the identification of smouldering disease…
- Conditions
- Multiple Sclerosis, Radiologically Isolated Syndrome, Clinically Isolated Syndrome
- Trial name
- PROCLAIM (NCT07032246)
- Testing
- quantitative brain MRI (icobrain mr), Standard of Care (SOC)
- Where
- 6 sites in Czechia, Germany and 1 more
- Volunteers
- 750 people
- Sponsor
- icometrix
Partial Epilepsies, Partial Onset Seizures
Study to Assess the Long-term Safety of Oral Lacosamide in Subjects With Partial-onset Seizures
The purpose of this study is to allow eligible subjects from the parent study, SP925 [NCT00655551] to continue lacosamide and to obtain additional long-term safety data
- Trial name
- NCT00655486
- Testing
- lacosamide
- Where
- 7 sites in United States
- Volunteers
- 97 people
- Sponsor
- UCB BIOSCIENCES, Inc.
Gait Disorders, Neurologic
Study to Assess Droxidopa in the Treatment of Freezing Of Gait Symptoms in Patients With Parkinson's Disease
Freezing of Gait (FoG) is a class of symptoms that occur in Parkinson's patients. Also called motor blocks, FoG is characterized by a sudden inability to move the lower extremities which usually lasts less than 10 seconds.
- Trial name
- NCT01331122
- Testing
- droxidopa
- Where
- 2 sites in United States, Canada
- Sponsor
- Chelsea Therapeutics
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.